It has been a week in which healthcare has rarely been out of the headlines on the London market. GSK reported on Wednesday, Haleon publishes a trading statement on Thursday, and AstraZeneca (LSE:AZN) brings the sequence to a close with its third-quarter results on Friday 30 October. With a market capitalisation of around £196bn, AstraZeneca carries considerable weight in the FTSE 100, so its update could matter for the index as a whole as well as for the sector.
The FTSE 100 closed Wednesday's session just 7.96 points higher at 10,694.50.
GSK sets a cautious tone
The week's first healthcare results did not go down well. GSK shares fell 4.78% to 1,831.50p on Wednesday, even though its sales and earnings beat forecasts. Reports noted that vaccines contributed less than consensus had expected and that investors were not persuaded by the company's push to build its pipeline.
The detail illustrates the kind of scrutiny large drugmakers face. GSK's third-quarter turnover was £8.9bn, up 5% at constant exchange rates, with Specialty Medicines up 15% to £3.9bn. Vaccines, however, fell 2% to £2.6bn, and Shingrix sales slipped 5% to £0.8bn. Core earnings per share rose 1% to 54.6p, and the company reaffirmed its 2026 guidance. Chief executive Luke Miels said GSK had delivered another good quarter, yet the market focused on the weaker parts of the mix.
The update was not short of pipeline and shareholder news, which makes the muted reception all the more telling. GSK highlighted US and Japanese approval of Hibsago for chronic hepatitis B, US approvals for Jemperli in a form of rectal cancer and Jideytro in a type of lung cancer, and the start of a phase III trial of an mRNA seasonal flu vaccine. It said it had made 18 of the 22 phase III starts planned for 2026. It also declared a 17p third-quarter dividend, expects 70p for the full year, and is targeting £1.9bn of annual savings by 2029 through its Accelerate Growth programme. No new share buyback was announced after the £2bn programme was completed in the second quarter.
Market reports said that personal care, drug and grocery stocks fell nearly 1.4% as a group on Wednesday, with Unilever (LSE:ULVR) also down 2.05% after its own update. That backdrop means AstraZeneca reports into a sector that has recently been treated cautiously by investors.
GSK's experience offers a general lesson. Beating headline forecasts does not ensure a positive share price reaction. Investors often look beneath the totals, at the performance of individual products or divisions, at guidance, and at the credibility of longer-term growth plans.
For large pharmaceutical companies, those themes typically include:
- Sales trends for the most important medicines and therapy areas.
- The progress of the drug pipeline, including trial readouts and regulatory approvals.
- Full-year guidance and any changes to it.
- Commentary on pricing, competition and the regulatory environment.
These are areas where pharmaceutical results generally attract attention; the information available here does not preview AstraZeneca's figures in detail, and no assumption is made about what the company will report in any of them.
The weight of a £196bn constituent
AstraZeneca's size gives its results particular significance for the index. A company with a market value of about £196bn can move the FTSE 100 noticeably on its own.
Because so much index value is concentrated in a small number of large companies, the reactions to a handful of results in a single week can shape the FTSE 100's overall direction. Wednesday was a case in point: market reports described UK shares as subdued, with bank gains offset by declines in GSK and Unilever.
Currency and rates in the background
Large FTSE 100 healthcare groups often earn much of their revenue overseas, and in general that means currency movements can affect how results look in sterling terms. Sterling closed Wednesday at about $1.3310 against the dollar and the euro stood at $1.1148. The ECB announces a rate decision on Thursday and the Bank of Japan follows on Friday, the same day as AstraZeneca's results.
In the US, the Federal Reserve held its target range at 3.75% to 4.00% on Wednesday, with two dissenters preferring a rise. The US 10-year Treasury yield was 5.03%. At home, the Budget was seen as largely uneventful; one market commentator called it "steady as she goes". The 10-year gilt yield eased to about 5.33%.
Key dates to watch
- Thursday 29 October 2026: Haleon's third-quarter trading statement, the middle leg of the week's healthcare results; the ECB also decides on rates.
- Friday 30 October 2026: AstraZeneca reports third-quarter results, alongside BP (LSE:BP.) and NatWest (LSE:NWG), while the Bank of Japan meets.
- Thursday 5 November 2026: The Bank of England's MPC decision and Monetary Policy Report.
- Wednesday 2 December 2026: FTSE Russell announces its December index review after the market close.
- Monday 21 December 2026: December index changes take effect at the open.
The bottom line
AstraZeneca closes a week in which healthcare and consumer names have been under the spotlight on the FTSE 100. GSK's 4.78% fall on Wednesday, despite beating forecasts, showed that investors are looking well beyond the headline numbers, and the wider personal care, drug and grocery group also lost ground. As a company valued at around £196bn, AstraZeneca has the scale to influence the index on its own, which makes Friday's update significant for the broader market as well as the sector.






Please wait processing your request...